Jan 29, 2013 by Dave WilliamsonFoolish Preview: Vertex EarningsTaking a look at the biotech's soon-to-be-reported 4th quarter.
Jan 28, 2013 by Dave WilliamsonFoolish Preview: Pfizer Earnings What to expect from the big pharma's fourth quarter.
Jan 28, 2013 by Dave WilliamsonFoolish Preview: Eli Lilly Earnings What to expect for the big pharma's fourth quarter.
Jan 28, 2013 by Dave WilliamsonKeryx: This Biotech Is No ZombieBack from the dead, courtesy of Zerenex.
Jan 26, 2013 by Dave WilliamsonFoolish Preview: Biogen EarningsWhat investors should look for in Biogen's fourth quarter.
Jan 25, 2013 by Dave WilliamsonSarepta Adds Another Supporter Wall Street continues to get bullish on the small cap.
Jan 25, 2013 by Dave WilliamsonWill Threshold's MAESTRO Hit the Right Note? The new phase 3 trial is critical for the company.
Jan 23, 2013 by Dave WilliamsonMAP Investors: X Marks the BuyoutMAP Pharmaceuticals' meteoric rise today.
Jan 23, 2013 by Dave WilliamsonFoolish Preview: Bristol-Myers SquibbWhat to expect from Bristol-Myers Squibb's earnings report.
Jan 23, 2013 by Dave Williamson and Max MacalusoCould Dendreon Be a Buyout Candidate?Is there still hope of a buyout for Dendreon?
Jan 23, 2013 by Dave WilliamsonFoolish Preview: Baxter EarningsWhat to expect from the earnings report from Baxter International.
Jan 23, 2013 by Dave WilliamsonFoolish Preview: Celgene EarningsWhat investors can expect from Celgene's earnings report.
Jan 22, 2013 by Dave WilliamsonFoolish Preview: Hill-Rom EarningsA peek at what's to come in the earnings report for this hospital bed and furniture maker.
Jan 22, 2013 by Dave WilliamsonFoolish Preview: Varian EarningsWhat to expect from Varian Medical Systems' earnings report.
Jan 22, 2013 by Dave WilliamsonFoolish Preview: St. Jude EarningsAfter a difficult 2012, what will this quarter say about St. Jude in 2013?
